adalimumab products — Medica
juvenile idiopathic arthritis (juvenile rheumatoid arthritis, juvenile spondyloarthropathy/active sacroiliac arthritis)
Initial criteria
- age ≥ 2 years
- EITHER (a) trial of one systemic therapy (e.g., methotrexate, sulfasalazine, leflunomide, or NSAID) OR (b) starting concurrently with methotrexate/sulfasalazine/leflunomide OR (c) absolute contraindication to these agents OR (d) aggressive disease as determined by prescriber
- prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- patient established on therapy ≥ 6 months
- beneficial clinical response by objective measure (e.g., MD global, PGA, JDAS, JSpADA, serum markers, or reduced corticosteroid dosage) OR improvement in symptoms/function/morning stiffness vs baseline
Approval duration
initial 6 months, reauth 1 year